Kriya Medical Technologies Secures Manufacturing License for KRIVIDA Trivus Respi Panel RT-qPCR Kit
Chennai : Kriya Medical Technologies, a leading medical devices company headquartered in Chennai, has received its manufacturing license from the Central Drugs Standard Control Organization (CDSCO) for its product KRIVIDA Trivus Respi Panel RT-qPCR Kit, a first of its kind kit that has the unique capability to simultaneously identify Respiratory Syncytial Virus (RSV), Influenza viruses and SARS-CoV-2 in patients presenting with respiratory tract infections.
KRIVIDA Trivus Respi Panel RT-qPCR kit has been validated by ICMR at National Institute of Virology, Pune, and the kit has shown 100% specificity and 99.11% sensitivity for the detection of all three viruses.
A key feature of this kit is its ability to detect RSV, a virus that primarily causes viral pneumonia in children under the age of 5 and contributes significantly to hospitalizations. Additionally, RSV is a common cause of lower respiratory tract diseases (LRTD) in older adults, potentially leading to life-threatening pneumonia and bronchiolitis. Hence, early detection of RSV is imperative for both infants and the elderly.
In India, influenza accounts for 35% of all respiratory tract infections. In severe cases, the progression from influenza-like illness (ILI) to acute lung injury and acute respiratory distress syndrome can be rapid, resulting in high mortality rates. The Krivida Trivus Respi Panel RT-qPCR Kit helps in early detection of influenza, thereby enabling the prompt initiation of specific antiviral medications.
The kit can also detect co-infections, which are associated with increased disease severity, morbidity, and mortality due to a weakened immune system. The Krivida Trivus Respi Panel RT-qPCR Kit is a valuable tool for improving diagnostic and infection control capacity.
Dr. Shanmugapriya, MD, R&D Head, Kriya Medical Technologies, said “12.9% of infant deaths in India is caused by pneumonia. 29% of infants with pneumonia are infected with Respiratory Syncytial Virus in India. The mortality rate of RSV infection in a healthy infant is 0.5 to 1.7% and is as high as 60% in immunocompromised infants. The rationale behind the design of Krivida Trivus Multiplex RT PCR kit is grounded in the recognition of the fact that timely and accurate diagnosis of RSV is key for avoiding severe forms of pneumonia and death, and this helps in significant reduction in infant mortality rate. We decided to include Influenza detection, as Influenza (A and B) causes 29% of pneumonia in infants and using specific antiviral drug in the earliest phase of illness can reduce the burden of complications’
Anu Moturi, CEO and Founder, Kriya Medical Technologies, said, “In the wake of the upcoming Flu season, the Krivida Trivus Respi Panel RT-qPCR Kit is timely and essential since it helps with accurate and rapid identification of the responsible pathogens, enabling healthcare providers to initiate appropriate treatments promptly, reducing the risk of complications and improving patient outcomes. It enables accurate identification of causative agents, enabling targeted and specific treatments resulting in an increased number of successful outcomes. Acquiring this license is yet another milestone and a step towards our vision of making good healthcare affordable and accessible to all. The Krivida Trivus Respi Panel RT-qPCR Kit is a testament to our commitment to innovation, addressing critical healthcare needs.
The kit seamlessly integrates with all available RT PCR instruments. This compatibility ensures that healthcare facilities can effortlessly incorporate the kit into their existing diagnostic infrastructure, optimizing operational efficiency.
“We strongly feel that incorporating Krivida Trivus into the existing RT-PCR infrastructure in laboratories will undoubtedly enhance the capacity of labs to offer a broader range of value-added diagnostic services. It’s a strategic move that aligns with our commitment to innovation and improved patient care. By simultaneously targeting three viral infections, as compared to running individual tests for each of these pathogens as currently available, the kit offers a 10X reduction in cumulative testing costs and 3X reduction in TAT.” Anu added